Company News
Abivax Shares Drop 32% After Malignancy Signals
Abivax’s Paris‑listed shares fell over 32% in early European trading on 2 June 2026 after trial data were released.
The 44‑week ulcerative colitis trial showed 50.8% (25 mg) and 51.3% (50 mg) remissio
